Verismo Therapeutics is a pioneer in dual-chain KIR-CAR technology, on track to bring its first asset into first-in-human clinical trials in 2023. Verismo is the only company developing the KIR-CAR platform, a modified NK-like receptor designed to improve persistence and efficacy against aggressive solid tumors. The KIR-CAR platform technology was developed specifically for advanced solid tumors, an area of high unmet medical need.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/28/23 | $7,000,000 | Pre-Series A |
BRV Capital Ignite Innovation | undisclosed |
| 07/18/23 | $17,000,000 | Pre-Series A |
Dongkoo Bio&Pharma HLB Co. HLB Innovation | undisclosed |
